Last update 19 Jun 2024

Metoclopramide Hydrochloride

Last update 19 Jun 2024

Overview

R&D Status

Clinical Result

Translational Medicine

Overview

Basic Info

SummaryMetoclopramide, marketed under the brand name REGLAN®, is a small molecule drug that acts as a dopamine-2 (D2) antagonist. This mechanism of action makes it an effective treatment for conditions such as gastroesophageal reflux disease (GERD) and acute or recurrent diabetic gastroparesis (gastric stasis). Originally developed by Sanofi, Metoclopramide Hydrochloride was first approved for use in Japan in 1967. It is commonly available in both oral and injectable formulations. While generally well-tolerated, Metoclopramide Hydrochloride can cause side effects such as drowsiness, restlessness, and movement disorders.

Drug Type

Small molecule drug

Synonyms

2-methoxy-4-amino-5-chloro-N,N-(dimethylaminoethyl)benzamide, 2-methoxy-5-chloroprocainamide, 4-amino-5-chloro-2-methoxy-N-(β-diethylaminoethyl)benzamide

+ [31]

Target

DRDs

Mechanism

DRDs antagonists(Dopamine receptors antagonists)

Therapeutic Areas

Nervous System DiseasesDigestive System DisordersEndocrinology and Metabolic Disease+ [3]

Active Indication

Drug-induced nausea and vomitingRadiation-induced nausea and vomitingVomiting+ [4]

Inactive Indication

Chemotherapy-induced nausea and vomitingCritical IllnessGastroparesis+ [1]

Originator Organization

Sanofi

Active Organization

Nichi-Iko Pharmaceutical Co., Ltd.

Evoke Pharma, Inc.

Sanofi

+ [3]

Inactive Organization

Hikma Pharmaceuticals USA, Inc.

Millennium Pharmaceuticals, Inc.

Salix Pharmaceuticals, Inc.

+ [1]

Drug Highest PhaseApproved

First Approval Date

JP (25 Mar 1967),

Decrease in appetiteNausea and vomiting

Regulation-

Structure

Molecular FormulaC14H26Cl3N3O3

InChIKeyIRQVJPHZDYMXNW-UHFFFAOYSA-N

CAS Registry5581-45-3

229

Clinical Trials associated with Metoclopramide Hydrochloride

NCT06379217 / Not yet recruitingPhase 1

A Phase I, Open-label, Multi-center Exploratory Safety and Efficacy Study With PSMA, SSTR2 and GRPR Targeted Radioligand Therapy in Metastatic Neuroendocrine Prostate Cancer.

The purpose of this study is to evaluate the change in the expression of treatment targets on the surface of tumor cells (Prostate Specific Membrane Antigen (PSMA), Somatostatin Receptor 2 (SSTR2), and Gonadotropin Releasing Hormone Receptor (GRPR)) between the start and after the completion of radioligand therapy (RLT). Study will use radioligand imaging (RLI) to determine predominantly expressed target on the surface of tumor cells. Based on predominant expression of target, corresponding RLT targeting PSMA, SSTR2, or GRPR RLT will be given for up to 6 cycles every 6 weeks as intravenous (i.v.) injection in participants with metastatic neuroendocrine prostate cancer (mNEPC).

Start Date18 Jun 2024

Sponsor / Collaborator

Novartis Pharmaceuticals Corp.

CTRI/2024/04/066529 / Not yet recruitingNot Applicable

To evaluate the effect of metoclopramide on gastric reserve volume after adequate fasting (8 hours for solids, 2 hours for clear fluids) in patients undergoing gynaecological surgeries under subarachnoid block in a double blind and randomised clinical trial

Start Date10 May 2024

Sponsor / Collaborator-

IRCT20151123025202N37 / RecruitingPhase 2/3

Comparison of the analgesic effect of metoclopramide and acetaminophen with metoclopramide and placebo in the management of acute migraine headache

Start Date04 May 2024

Sponsor / Collaborator

Hamedan University of Medical Sciences

100 Clinical Results associated with Metoclopramide Hydrochloride

100 Translational Medicine associated with Metoclopramide Hydrochloride

100 Patents (Medical) associated with Metoclopramide Hydrochloride

6,101

Literatures (Medical) associated with Metoclopramide Hydrochloride

01 Mar 2024·European journal of hospital pharmacy : science and practice

Rare case report of moxifloxacin-induced persistent hiccups

Article

Author: Zhou, Jing ; Li, Songlong ; Wang, Fei

Moxifloxacin is a broad-spectrum antimicrobial agent that is commonly used in clinical practice. Here we report an unusual case of a patient with persistent hiccups caused by moxifloxacin. A man aged in his 40s was treated with moxifloxacin for tuberculous pleurisy. Hiccups occurred 2 hours after intravenous injection of moxifloxacin and lasted into evening. On the second day after injection, hiccups occurred again and made it difficult for him to fall asleep. The clinician ruled out gastrointestinal disease, nervous system disease, electrolyte disturbance and other factors. On assessing causality of the adverse drug reaction, the Naranjo scale for moxifloxacin was six, indicating a probable relationship of hiccups with moxifloxacin. Hiccups stopped 2 min after intramuscular injection of metoclopramide. To our knowledge, this is the first case report about moxifloxacin-induced persistent hiccups. Clinicians should be aware of the rare adverse reaction.

01 Jan 2024·Revista espanola de enfermedades digestivas

OGILVIE, WHEN MEDICAL AND ENDOSCOPIC TREATMENT FAIL

Article

Author: Quiñones Castro, Raisa ; Domínguez Carbajo, Ana Belén ; González Puente, Isabel ; Borrego Rivas, Sandra

Ogilvie syndrome is a functional disorder of colonic motility that causes acute and progressive dilation, which can lead to necrosis and perforation. Early diagnosis and management are essential to avoid serious complications. The case of a patient with Ogilvie syndrome refractory to medical and endoscopic treatment that required surgery is presented. This is a 68-year-old man with decreased level of consciousness and abdominal distension for 3 days. Last bowel movement 4 days ago. The data and tests appear in table 1. We are faced with a patient with neurological alteration and hemodynamically unstable secondary to complicated Ogilvie syndrome. After admission to the ICU, where a 2.5 mg bolus of neostigmine was administered, he was transferred to the ward. Despite 250 mg of intravenous erythromycin every 6 hours together with metoclopramide every 8 hours, high doses of polyethylene glycol and daily cleansing enemas and rectal catheterization, only a brief and mild improvement is achieved. Given the failure of conservative measures, colectomy was performed, achieving complete resolution. Ogilvie syndrome is a functional disorder1 that usually associates predisposing factors that impact intestinal motility 2 ; In our case: bedridden, the use of anticholinergics, hydroelectric alteration both due to the use of antidepressants and the creation of a third space secondary to colonic dilation and severe intestinal ischemia². In one third it is resolved by early correction of the triggering factors, adding neostigmine if necessary with high rates of effectiveness¹. In our case, a second bolus of neostigmine could have been administered or even as an infusion since greater efficacy has been demonstrated in this way given its short half-life². Electrolyte imbalance is a predictor of poor response to neostigmine, a factor that was associated with our patient 3. Colonic decompression and finally surgery are reserved as a last measure, being necessary in a very small percentage as in this case 1. As a preventive measure, the administration of 29.5 g of oral polyethylene glycol per day has been effective 4. Therefore, we should suspect Ogilvie syndrome in patients with predisposing factors who present acute dilation of the colon without mechanical obstruction, and although it usually resolves with medical and endoscopic treatment, we should not delay surgery to avoid complications.

01 Jan 2024·Handbook of clinical neurology

Nonspecific analgesics, combination analgesics, and antiemetics

Review

Author: Tassorelli, Cristina ; Pocora, Maria Magdalena ; Martinelli, Daniele

The acute treatment of migraine attacks should provide rapid, effective, and long-lasting symptom relief, causing minimal adverse effects. For this purpose, there are several specific and nonspecific acute treatments. In this chapter, we focus on molecules not specifically designed for migraines, including anti-inflammatory not specific analgesics, such as acetaminophen, acetylsalicylic acid, and other non-steroidal anti-inflammatory drugs (or COX-2 inhibitors); antinausea medications like metoclopramide or prochlorperazine, which can alleviate sickness and vomiting associated with migraines, and may also have a direct painkiller effect; combinations of simple analgesics or association of a painkiller with caffeine. This stimulant can help enhance the pain-relieving effects of some headache medications and provide its own analgesic effect; physical approaches: applying cold packs or heating pads on the forehead or neck, can help relieve migraine pain; other classes with limited to no evidence to support their use, such as intravenous corticosteroids or antiepileptic drugs as sodium valproate. Finally, we will briefly mention opioids, barbiturates, or medical cannabis, bearing in mind that their use is not recommended by current guidelines.

News (Medical) associated with Metoclopramide Hydrochloride

21 May 2024

·www.prnewswire.com

Neurocrine Biosciences Announces Publication of Phase 3 KINECT®-4 Post Hoc Analysis Demonstrating Clinically Meaningful and Sustained Improvement in Tardive Dyskinesia With Long-Term Use of INGREZZA® (valbenazine) Capsules

SAN DIEGO, May 21, 2024 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced the publication of data from a post hoc analysis of the Phase 3 KINECT®-4 study of INGREZZA® (valbenazine) capsules in the Journal of Clinical Psychopharmacology. The analysis assessed long-term outcomes relevant to the real-world management of tardive dyskinesia (TD) and demonstrated that nearly all study participants met the threshold for clinically meaningful improvements in TD symptom severity by Week 48. "TD is a persistent, debilitating disorder requiring continuous treatment to effectively and sustainably improve symptoms over time," said Eiry W. Roberts, M.D., Chief Medical Officer at Neurocrine Biosciences. "This post hoc analysis, along with previous long-term analyses, demonstrate the reliable, long-term efficacy and tolerability of one-capsule, once-daily INGREZZA to help inform use of this treatment in clinical practice." The KINECT-4 study implemented an open-label design and on-site assessments of TD severity. The analysis included 103 participants from the Phase 3 KINECT-4 study who completed 48 weeks of treatment with INGREZZA. KINECT-4 was designed to be representative of clinical practice to provide insight into real-world management of TD with INGREZZA. Key highlights include: At Week 4, 55% of participants experienced clinically meaningful improvement in TD symptom severity on the lowest starting dose (40 mg). A clinically meaningful improvement was defined as a reduction of at least 2 points in the Abnormal Involuntary Movement Scale (AIMS) total score used to assess the severity of involuntary movements in different body regions. Ninety-five percent of participants reached this threshold as soon as Week 24, with 97% achieving it by Week 48. TD improvement was sustained throughout treatment, with an AIMS mean total score reduction from baseline to Week 48 of 10.5. Eighty-six percent of participants met the response threshold of at least 50% AIMS improvement, and 52% met the higher threshold of at least 70% AIMS improvement at Week 48. More than 88% of patients and healthcare professionals rated participants' symptoms as "much improved" or "very much improved" at Week 48, as measured by the Patient Global Impression of Change and Clinical Global Impression of Change-TD, respectively. Overall, INGREZZA was generally well tolerated. The most common treatment emergent adverse events reported from Weeks 4 to 48 included urinary tract infection (8.5%) and headache (5.2%). About the KINECT- 4 Phase 3 Study KINECT®-4 is a Phase 3, open-label study, in which 163 participants with moderate to severe TD and underlying schizophrenia, schizoaffective disorder or mood disorder (including bipolar disorder or major depressive disorder) received 48 weeks of open-label treatment with once-daily INGREZZA (40 mg or 80 mg capsules) followed by a four-week washout. Dosing was initiated at 40 mg/day in all participants, with escalation to 80 mg/day at Week 4 based on effectiveness and tolerability. Dose reduction to 40 mg was allowed in participants who could not tolerate the 80 mg dose. Patients were discontinued if the new dose was not tolerated. Participants experienced TD improvements during long-term treatment as demonstrated by mean change from baseline to Week 48 in AIMS total score (sum of items 1-7, evaluated by site raters) with INGREZZA 40 mg/day (-10.2) or 80 mg/day (-11.0). Consistent with previous studies, INGREZZA was generally well tolerated. After Week 4, treatment emergent adverse events (TEAEs) that occurred in ≥ 5% of all participants (combined dose groups) were urinary tract infection (8.5%) and headache (5.2%). Changes from baseline in psychiatric stability, vital signs, electrocardiogram parameters and laboratory test values were generally small and not clinically significant. About Tardive Dyskinesia (TD) Tardive dyskinesia (TD) is a movement disorder that is characterized by uncontrollable, abnormal and repetitive movements of the face, torso and/or other body parts, which may be disruptive and negatively impact patients. The condition is associated with taking certain kinds of mental health medicines (antipsychotics) that help control dopamine receptors in the brain. Taking antipsychotics commonly prescribed to treat mental illnesses such as major depressive disorder, bipolar disorder, schizophrenia and schizoaffective disorder, and other prescription medicines (metoclopramide and prochlorperazine) used to treat gastrointestinal disorders are associated with TD. In patients with TD, these treatments are thought to result in irregular dopamine signaling in a region of the brain that controls movement. The symptoms of TD can be severe and are often persistent and irreversible. TD is estimated to affect approximately 600,000 people in the United States. About INGREZZA® (valbenazine) Capsules INGREZZA is the only one-capsule, once-daily selective vesicular monoamine transporter 2 (VMAT2) inhibitor approved by the U.S. Food and Drug Administration for the treatment of adults with tardive dyskinesia and the treatment of chorea associated with Huntington's disease (HD). INGREZZA, developed by Neurocrine Biosciences, selectively inhibits VMAT2 with no appreciable binding affinity for VMAT1, dopaminergic (including D2), serotonergic, adrenergic, histaminergic or muscarinic receptors. While the specific way INGREZZA works to treat TD and HD chorea is not fully understood, INGREZZA selectively targets VMAT2 to inhibit the release of dopamine, a chemical in the brain that helps control movement. INGREZZA is believed to reduce extra dopamine signaling, which may lead to fewer uncontrollable movements. Additionally, INGREZZA can be taken as one capsule, once daily together with most psychiatric medications such as antipsychotics or antidepressants. INGREZZA dosages approved for use are 40 mg, 60 mg and 80 mg capsules. INGREZZA is not approved in any other dosage form. Important Information Approved Uses INGREZZA® (valbenazine) capsules or INGREZZA® SPRINKLE (valbenazine) capsules are prescription medicines used to treat adults with: movements in the face, tongue, or other body parts that cannot be controlled (tardive dyskinesia). involuntary movements (chorea) of Huntington's disease. INGREZZA or INGREZZA SPRINKLE do not cure the cause of involuntary movements, and do not treat other symptoms of Huntington's disease, such as problems with thinking or emotions. It is not known if INGREZZA or INGREZZA SPRINKLE is safe and effective in children. IMPORTANT SAFETY INFORMATION VMAT2 inhibitors, including INGREZZA and INGREZZA SPRINKLE, can cause serious side effects in people with Huntington's disease, including: depression, suicidal thoughts, or suicidal actions. Tell your healthcare provider before you start taking INGREZZA or INGREZZA SPRINKLE if you have Huntington's disease and are depressed (have untreated depression or depression that is not well controlled by medicine) or have suicidal thoughts. Pay close attention to any changes, especially sudden changes, in mood, behaviors, thoughts, or feelings. This is especially important when INGREZZA or INGREZZA SPRINKLE is started and when the dose is changed. Call your healthcare provider right away if you become depressed, have unusual changes in mood or behavior, or have thoughts of hurting yourself. Do not take INGREZZA or INGREZZA SPRINKLE if you: are allergic to valbenazine, or any of the ingredients in INGREZZA or INGREZZA SPRINKLE. INGREZZA or INGREZZA SPRINKLE can cause serious side effects, including: Allergic reactions. Allergic reactions, including an allergic reaction that causes sudden swelling called angioedema, can happen after taking the first dose or after many doses of INGREZZA or INGREZZA SPRINKLE. Signs and symptoms of allergic reactions and angioedema include: trouble breathing or shortness of breath, swelling of your face, lips, eyelids, tongue, or throat, or other areas of your skin, trouble with swallowing, or rash, including raised, itchy red areas on your skin (hives). Swelling in the throat can be life-threatening and can lead to death. Stop taking INGREZZA or INGREZZA SPRINKLE and go to the nearest emergency room right away if you develop these signs and symptoms of allergic reactions and angioedema. Sleepiness and tiredness that could cause slow reaction times (somnolence and sedation). Do not drive a car or operate dangerous machinery until you know how INGREZZA or INGREZZA SPRINKLE affects you. Drinking alcohol and taking other medicines may also cause sleepiness during treatment with INGREZZA or INGREZZA SPRINKLE. Heart rhythm problems (QT prolongation). INGREZZA or INGREZZA SPRINKLE may cause a heart rhythm problem known as QT prolongation. You have a higher chance of getting QT prolongation if you also take certain other medicines during treatment with INGREZZA or INGREZZA SPRINKLE. Tell your healthcare provider right away if you develop any signs or symptoms of QT prolongation, including: fast, slow, or irregular heartbeat (heart palpitations), shortness of breath, dizziness or lightheadedness, or fainting or feeling like you are going to faint. Neuroleptic Malignant Syndrome (NMS). NMS is a serious condition that can lead to death. Call a healthcare provider right away or go to the nearest emergency room if you develop these symptoms and they do not have another obvious cause: high fever, stiff muscles, problems thinking, irregular pulse or blood pressure, increased sweating, or very fast or uneven heartbeat. Parkinson-like symptoms. Symptoms include: body stiffness, drooling, trouble moving or walking, trouble keeping your balance, shaking (tremors), or falls. Before taking INGREZZA or INGREZZA SPRINKLE, tell your healthcare provider about all of your medical conditions including if you: have liver or heart problems, are pregnant or plan to become pregnant, or are breastfeeding or plan to breastfeed. Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. Make sure you tell all of your healthcare providers that you are taking INGREZZA or INGREZZA SPRINKLE. Taking INGREZZA or INGREZZA SPRINKLE with certain other medicines may cause serious side effects. Especially tell your healthcare provider if you: take digoxin or take or have taken a monoamine oxidase inhibitor (MAOI) medicine. You should not take INGREZZA or INGREZZA SPRINKLE if you are taking, or have stopped taking, a MAOI within the last 14 days. The most common side effects of INGREZZA or INGREZZA SPRINKLE in people with tardive dyskinesia are sleepiness and tiredness. The most common side effects of INGREZZA or INGREZZA SPRINKLE in people with chorea associated with Huntington's disease include sleepiness and tiredness, raised itchy red areas on your skin (hives), rash, and trouble getting to sleep or staying asleep. These are not all of the possible side effects of INGREZZA or INGREZZA SPRINKLE. Call your doctor for medical advice about side effects. You are encouraged to report negative side effects of prescription drugs to the FDA. Visit MedWatch at or call 1-800-FDA-1088. Dosage Forms and Strengths: INGREZZA and INGREZZA SPRINKLE are available in 40 mg, 60 mg, and 80 mg capsules. Please see full Prescribing Information , including Boxed Warning, and Medication Guide. About Neurocrine Biosciences, Inc. Neurocrine Biosciences is a leading neuroscience-focused, biopharmaceutical company with a simple purpose: to relieve suffering for people with great needs, but few options. We are dedicated to discovering and developing life-changing treatments for patients with under-addressed neurological, neuroendocrine and neuropsychiatric disorders. The company's diverse portfolio includes FDA-approved treatments for tardive dyskinesia, chorea associated with Huntington's disease, endometriosis* and uterine fibroids*, as well as a robust pipeline including multiple compounds in mid- to late-phase clinical development across our core therapeutic areas. For three decades, we have applied our unique insight into neuroscience and the interconnections between brain and body systems to treat complex conditions. We relentlessly pursue medicines to ease the burden of debilitating diseases and disorders, because you deserve brave science. For more information, visit neurocrine.com, and follow the company on LinkedIn, X (formerly Twitter) and Facebook. (*in collaboration with AbbVie) The NEUROCRINE BIOSCIENCES Logo Lockup, NEUROCRINE, YOU DESERVE BRAVE SCIENCE, KINECT and INGREZZA are registered trademarks of Neurocrine Biosciences, Inc. Forward-Looking Statements In addition to historical facts, this press release contains forward-looking statements that involve a number of risks and uncertainties. These statements include, but are not limited to, statements regarding the potential benefits to be derived from INGREZZA and the value INGREZZA may bring to patients. Among the factors that could cause actual results to differ materially from those indicated in the forward-looking statements are: risks and uncertainties associated with Neurocrine Biosciences' business and finances in general, as well as risks and uncertainties associated with the commercialization of INGREZZA; risks that clinical trial activities may not be predictive of real-world results or of results in subsequent clinical trials; risks that INGREZZA may be precluded from commercialization by the proprietary rights of third parties, or have unintended side effects or adverse reactions; risks and uncertainties relating to competitive products and technological changes that may limit demand for INGREZZA; risks associated with our dependence on third parties for development and manufacturing activities related to INGREZZA and our product candidates, and our ability to manage these third parties; risks that the FDA or other regulatory authorities may make adverse decisions regarding our products or product candidates; risks that our products, and/or our product candidates may be precluded from commercialization by the proprietary or regulatory rights of third parties, or have unintended side effects, adverse reactions or incidents of misuse; risks associated with potential generic entrants for our products; and other risks described in the Company's periodic reports filed with the Securities and Exchange Commission, including without limitation the Company's quarterly report on Form 10-Q for the quarter ended March 31, 2024. Neurocrine Biosciences disclaims any obligation to update the statements contained in this press release after the date hereof. Reference: Correll CU, Citrome L, Singer C, Lindenmayer JP, Zinger C, Liang G, Dunayevich E, Marder SR. Sustained treatment response and global improvements with long-term valbenazine in patients with tardive dyskinesia. J Clin Psychopharmacology. May 20, 2024. doi:10.1097/JCP.0000000000001860 © 2024 Neurocrine Biosciences, Inc. All Rights Reserved. SOURCE Neurocrine Biosciences, Inc.

Phase 3Clinical ResultDrug Approval

16 May 2024

·www.globenewswire.com

Evoke Pharma to Present Additional GIMOTI Healthcare Utilization Data Focused on Gastroparesis Care Insights in Women at 2024 Digestive Disease Week (DDW) Conference

Evoke commercial booth located at site #737SOLANA BEACH, Calif., May 16, 2024 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with an emphasis on GIMOTI® (metoclopramide) nasal spray, announced that its abstract demonstrating enhanced gastroparesis care in women using nasal metoclopramide will be presented at the 2024 Digestive Disease Week Conference (DDW 2024) taking place May 18-21, 2024 in Washington D.C. "Being patient-centric is at the core of our mission as a company. At DDW 2024, our poster presentation will highlight the additional benefits of GIMOTI with improving healthcare experiences and patient outcomes. We are particularly excited about the positive therapeutic impact on women, the demographic most affected by gastroparesis worldwide. This event will also provide us with the opportunity to further showcase the fewer physician office visits, inpatient hospitalizations, and emergency department visits for women suffering from diabetic gastroparesis by treating with Gimoti compared to oral metoclopramide,” commented Matt D’Onofrio, CEO of Evoke Pharma. Details of the poster presentation are as follows: Abstract Title: Transforming Diabetic Gastroparesis Care in Women: Insights from Nasal Metoclopramide Usage Presenter & Lead Author: David C. Kunkel, MD, Gastroenterologist and Associate Professor of Medicine, University of San Diego Health Presentation Session: Gastroparesis and Small Intestinal Dysmotility Poster#: 1663 Date & Time: Monday, May 20 from 12:30 – 1:30 p.m. ET Abstracts will be available on the DDW ePosters site and to conference attendees in the DDW meeting planner and mobile app after 12:01 a.m. on Sunday, May 19, 2024. Check out Evoke Pharma at DDW 2024: For more information on GIMOTI or our poster presentation, visit Evoke at booth #737. About Digestive Disease Week® (DDW) Digestive Disease Week® (DDW) is the largest international gathering of physicians, researchers and academics in the fields of gastroenterology, hepatology, endoscopy and gastrointestinal surgery. Jointly sponsored by the American Association for the Study of Liver Diseases (AASLD), the American Gastroenterological Association (AGA), the American Society for Gastrointestinal Endoscopy (ASGE) and the Society for Surgery of the Alimentary Tract (SSAT), DDW is an in-person and online meeting from May 18-21, 2024. The meeting showcases more than 4,400 abstracts and hundreds of lectures on the latest advances in GI research, medicine and technology. More information can be found at www.ddw.org. About Gimoti® (metoclopramide) nasal spray GIMOTI is indicated for the relief of symptoms in adults with acute and recurrent diabetic gastroparesis. Important Safety Information WARNING: TARDIVE DYSKINESIA Metoclopramide can cause tardive dyskinesia (TD), a serious movement disorder that is often irreversible. The risk of developing TD increases with duration of treatment and total cumulative dosage.Discontinue GIMOTI in patients who develop signs or symptoms of TD. In some patients, symptoms may lessen or resolve after metoclopramide is stopped.Avoid treatment with metoclopramide (all dosage forms and routes of administration) for longer than 12 weeks because of the increased risk of developing TD with longer-term use. GIMOTI is not recommended for use in: Pediatric patients due to the risk of developing tardive dyskinesia (TD) and other extrapyramidal symptoms as well as the risk of methemoglobinemia in neonates.Moderate or severe hepatic impairment (Child-Pugh B or C), moderate or severe renal impairment (creatinine clearance less than 60 mL/minute), and patients concurrently using strong CYP2D6 inhibitors due to the risk of increased drug exposure and adverse reactions. GIMOTI is contraindicated: In patients with a history of tardive dyskinesia (TD) or a dystonic reaction to metoclopramide.When stimulation of gastrointestinal motility might be dangerous (e.g., in the presence of gastrointestinal hemorrhage mechanical obstruction, or perforation).In patients with pheochromocytoma or other catecholamine-releasing paragangliomas. Metoclopramide may cause a hypertensive/pheochromocytoma crisis, probably due to release of catecholamines from the tumor.In patients with epilepsy. Metoclopramide may increase the frequency and severity of seizures.In patients with hypersensitivity to metoclopramide. Reactions have included laryngeal and glossal angioedema and bronchospasm. Potential adverse reactions associated with metoclopramide include: Tardive dyskinesia (TD), other extrapyramidal effects (EPS), parkinsonism symptoms, motor restlessness, neuroleptic malignant syndrome (NMS), depression, suicidal ideation and suicide, hypertension, fluid retention, hyperprolactinemia, effects on the ability to drive and operate machinery. Most common adverse reactions (≥5%) for GIMOTI are: dysgeusia, headache, and fatigue. These are not all of the possible side effects of GIMOTI. Call your doctor for medical advice about whether you should take GIMOTI and the possible risk factors and side effects. You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088. About Evoke Pharma, Inc. Evoke is a specialty pharmaceutical company focused primarily on the development of drugs to treat GI disorders and diseases. The company developed, commercialized and markets GIMOTI, a nasal spray formulation of metoclopramide, for the relief of symptoms associated with acute and recurrent diabetic gastroparesis in adults. Diabetic gastroparesis is a GI disorder affecting millions of patients worldwide, in which the stomach takes too long to empty its contents resulting in serious GI symptoms as well as other systemic complications. The gastric delay caused by gastroparesis can compromise absorption of orally administered medications. Prior to FDA approval to commercially market GIMOTI, metoclopramide was only available in oral and injectable formulations and remains the only drug currently approved in the United States to treat gastroparesis. Safe Harbor Statement Evoke cautions you that statements included in this press release that are not a description of historical facts are forward-looking statements. In some cases, you can identify forward-looking statements by terms such as “may,” “will,” “should,” “expect,” “plan,” “anticipate,” “could,” “intend,” “target,” “project,” “contemplates,” “believes,” “estimates,” “predicts,” “potential” or “continue” or the negatives of these terms or other similar expressions. These statements are based on the company’s current beliefs and expectations. These forward-looking statements include statements regarding: guidance regarding 2024 net product sales; potential future prescribing trends for GIMOTI based on Evoke’s or EVERSANA’s marketing efforts; Evoke’s commercialization plans, including the potential that GIMOTI could become the standard of care for gastroparesis; the potential for additional funds from the exercise of outstanding warrants and Evoke’s expected cash runway. The inclusion of forward-looking statements should not be regarded as a representation by Evoke that any of its plans will be achieved. Actual results may differ from those set forth in this press release due to the risks and uncertainties inherent in Evoke’s business, including, without limitation: Evoke may not be able to achieve its guidance for 2024 including as a result of decreased demand for GIMOTI; Evoke’s and EVERSANA’s ability to successfully drive market demand for GIMOTI; Evoke’s ability to obtain additional financing as needed to support its operations; Evoke may use its capital resources sooner than expected; warrant holders may choose not to exercise any of the outstanding warrants; Evoke’s dependence on third parties for the manufacture of GIMOTI; Evoke is entirely dependent on the success of GIMOTI; inadequate efficacy or unexpected adverse side effects relating to GIMOTI that could result in recalls or product liability claims; Evoke’s ability to maintain intellectual property protection for GIMOTI; and other risks and uncertainties detailed in Evoke’s prior press releases and in the periodic reports it files with the Securities and Exchange Commission. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof, and Evoke undertakes no obligation to revise or update this press release to reflect events or circumstances after the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement. This caution is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Investor & Media Contact:Daniel Kontoh-BoatengDKB PartnersTel: 862-213-1398dboateng@dkbpartners.net

Drug Approval

14 May 2024

·www.globenewswire.com

Evoke Pharma Reports First Quarter 2024 Financial Results

114% year-over-year increase in net product sales70% prescriber growth in Q1 2024 compared to Q4 2023Growing sales metrics reaffirms company’s $14M net revenue guidance for 2024 SOLANA BEACH, Calif., May 14, 2024 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with an emphasis on GIMOTI® (metoclopramide) nasal spray, today announced its financial results for the first quarter ended March 31, 2024, and recent corporate developments. Matt D’Onofrio, CEO of Evoke Pharma commented, “The results achieved in the first quarter of 2024 reflect continued momentum with the adoption of GIMOTI. The real-world healthcare utilization data, including outcomes from over 500 patients, have consistently supported GIMOTI's efficacy for diabetic gastroparesis treatment compared to oral. Moreover, testimonials from leading physicians and the positive experiences shared by patients underscore the growing demand and trust in GIMOTI.” “In the first quarter of 2024, our net revenue of approximately $1.7 million faced marginal impacts from transient challenges, including a cyberattack on the largest U.S. medical claims processor and an increase in co-pay expenses covered by Evoke. The increase in co-pay expenses was partly due to lower payor reimbursements against higher patient deductibles typical at the year's start. The cyberattack in late February also disrupted new patient enrollments and refill adjudications for GIMOTI. Despite these obstacles, our adaptive strategies and resilience are yielding positive results. Notably, we've achieved a 70% quarter-over-quarter growth in prescriber numbers and a 10% increase in medication fills. Additionally, our strengthened partnership with ASPN Pharmacies is poised to further enhance our service delivery and patient reach. We are confident that the issues from this quarter will fully resolve as the year progresses. Coupled with our strong performance on key sales indicators, we anticipate accelerated growth throughout the remainder of 2024,” Mr. D’Onofrio continued. First Quarter 2024 Developments and Recent Highlights: Maximizing GIMOTI Awareness Building Efforts through KOLs & Conferences – Held virtual webinar featuring Michael Cline, DO., Medical Director Gastroparesis Clinic at the Cleveland Clinic in April to discuss compelling healthcare resource utilization data showing improved hospitilization rates, and his view on patient experience with GIMOTI.– Abstract focused on the healthcare resource utilization data of diabetic gastroparesis care in women using nasal metoclopramide to be presented at Digestive Disease Week (“DDW”) 2024 in Washington D.C.Transitioned Pharmacy Service Partnership & Initiated First Year of Distribution with ASPN Pharmacies– Scaling up GIMOTI distribution infrastructure and improving patient outcomes with access to ASPN’s expansive pharmacy network. Initiated pharmacy service agreement with ASPN in November 2023.Improved Cash Position– In Q1, the Company raised $8.8M in gross proceeds from a public offering and subsequent exercise of warrants with fundamental, healthcare-oriented institutional investors providing the company runway into the fourth quarter of 2024 with up to an additional $21.8M available if common stock warrants are exercised in full. "During our recent Key Opinion Leader (KOL) webinar, Dr. Michael Cline from the Cleveland Clinic discussed the limitations of oral metoclopramide for treating gastroparesis, noting its unpredictable effects due to gastric emptying variations. GIMOTI addresses these issues with its nasal delivery system, bypassing the faulty GI track in these patients. Moving forward, we will amplify our promotional efforts for GIMOTI through the insights of our KOLs, real-world data, and conferences such as the upcoming Digestive Disease Week (DDW). Later this month at DDW we will present data on the clinical use of nasal metoclopramide in women with gastroparesis, highlighting its benefits and practical application,” Mr. D’Onofrio concluded. Fourth Quarter and Full Year 2023 Financial Review and Outlook For the first quarter of 2024, net product sales were approximately $1.7 million compared with $0.8 million during the first quarter of 2023, and the net loss was approximately $1.6 million, or $0.17 per share compared with $2.2 million, or $0.67 per share, for the first quarter of 2023. For the first quarter of 2024, selling, general and administrative expenses were approximately $3.1 million compared to $2.8 million for the first quarter of 2023. The increases were due to higher professional fees and reimbursement and profit-sharing activity with EVERSANA. Total operating expenses for the first quarter of 2023 were approximately $3.2 million compared to $3.0 million for the same period in 2023. As of March 31, 2024, cash and cash equivalents were approximately $9.7M which includes the funds recently raised from our public offering and related warrant exercises. We believe, based on our current operating plan, that our existing cash and cash equivalents, as well as future cash flows from net product sales of GIMOTI, will be sufficient to fund our operations into the first quarter of 2025. Evoke reiterates its net revenue guidance in 2024 of approximately $14 million. Evoke’s 2024 guidance is dependent on its current business and expectations, including recent growth rates in net sales, assumptions regarding reimbursements and prescription fills, as well as factors that are outside of our control, such as the global macroeconomic and geopolitical environment, continued supply chain constraints and inflationary pressures. About Evoke Pharma, Inc. Evoke is a specialty pharmaceutical company focused primarily on the development of drugs to treat GI disorders and diseases. The company developed, commercialized and markets GIMOTI, a nasal spray formulation of metoclopramide, for the relief of symptoms associated with acute and recurrent diabetic gastroparesis in adults. Diabetic gastroparesis is a GI disorder affecting millions of patients worldwide, in which the stomach takes too long to empty its contents resulting in serious GI symptoms as well as other systemic complications. The gastric delay caused by gastroparesis can compromise absorption of orally administered medications. Prior to FDA approval to commercially market GIMOTI, metoclopramide was only available in oral and injectable formulations and remains the only drug currently approved in the United States to treat gastroparesis. Visit www.EvokePharma.com for more information.Follow GIMOTI on FacebookFollow Evoke Pharma on FacebookFollow Evoke Pharma on LinkedInFollow Evoke Pharma on Twitter About Gimoti® (metoclopramide) nasal spray GIMOTI is indicated for the relief of symptoms in adults with acute and recurrent diabetic gastroparesis. Important Safety Information WARNING: TARDIVE DYSKINESIA Metoclopramide can cause tardive dyskinesia (TD), a serious movement disorder that is often irreversible. The risk of developing TD increases with duration of treatment and total cumulative dosage.Discontinue GIMOTI in patients who develop signs or symptoms of TD. In some patients, symptoms may lessen or resolve after metoclopramide is stopped.Avoid treatment with metoclopramide (all dosage forms and routes of administration) for longer than 12 weeks because of the increased risk of developing TD with longer-term use. GIMOTI is not recommended for use in: Pediatric patients due to the risk of developing tardive dyskinesia (TD) and other extrapyramidal symptoms as well as the risk of methemoglobinemia in neonates.Moderate or severe hepatic impairment (Child-Pugh B or C), moderate or severe renal impairment (creatinine clearance less than 60 mL/minute), and patients concurrently using strong CYP2D6 inhibitors due to the risk of increased drug exposure and adverse reactions. GIMOTI is contraindicated: In patients with a history of tardive dyskinesia (TD) or a dystonic reaction to metoclopramide.When stimulation of gastrointestinal motility might be dangerous (e.g., in the presence of gastrointestinal hemorrhage mechanical obstruction, or perforation).In patients with pheochromocytoma or other catecholamine-releasing paragangliomas. Metoclopramide may cause a hypertensive/pheochromocytoma crisis, probably due to release of catecholamines from the tumor.In patients with epilepsy. Metoclopramide may increase the frequency and severity of seizures.In patients with hypersensitivity to metoclopramide. Reactions have included laryngeal and glossal angioedema and bronchospasm. Potential adverse reactions associated with metoclopramide include: Tardive dyskinesia (TD), other extrapyramidal effects (EPS), parkinsonism symptoms, motor restlessness, neuroleptic malignant syndrome (NMS), depression, suicidal ideation and suicide, hypertension, fluid retention, hyperprolactinemia, effects on the ability to drive and operate machinery. Most common adverse reactions (≥5%) for GIMOTI are: dysgeusia, headache, and fatigue. These are not all of the possible side effects of GIMOTI. Call your doctor for medical advice about whether you should take GIMOTI and the possible risk factors and side effects. You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088. Safe Harbor Statement Evoke cautions you that statements included in this press release that are not a description of historical facts are forward-looking statements. In some cases, you can identify forward-looking statements by terms such as “may,” “will,” “should,” “expect,” “plan,” “anticipate,” “could,” “intend,” “target,” “project,” “contemplates,” “believes,” “estimates,” “predicts,” “potential” or “continue” or the negatives of these terms or other similar expressions. These statements are based on the company’s current beliefs and expectations. These forward-looking statements include statements regarding: guidance regarding 2024 net product sales; potential future prescribing trends for GIMOTI based on Evoke’s or EVERSANA’s marketing efforts; Evoke’s commercialization plans, including the potential that GIMOTI could become the standard of care for gastroparesis; the potential for additional funds from the exercise of outstanding warrants and Evoke’s expected cash runway. The inclusion of forward-looking statements should not be regarded as a representation by Evoke that any of its plans will be achieved. Actual results may differ from those set forth in this press release due to the risks and uncertainties inherent in Evoke’s business, including, without limitation: Evoke may not be able to achieve its guidance for 2024 including as a result of decreased demand for GIMOTI; Evoke’s and EVERSANA’s ability to successfully drive market demand for GIMOTI; Evoke’s ability to obtain additional financing as needed to support its operations; Evoke may use its capital resources sooner than expected; warrant holders may choose not to exercise any of the outstanding warrants; Evoke’s dependence on third parties for the manufacture of GIMOTI; Evoke is entirely dependent on the success of GIMOTI; inadequate efficacy or unexpected adverse side effects relating to GIMOTI that could result in recalls or product liability claims; Evoke’s ability to maintain intellectual property protection for GIMOTI; and other risks and uncertainties detailed in Evoke’s prior press releases and in the periodic reports it files with the Securities and Exchange Commission. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof, and Evoke undertakes no obligation to revise or update this press release to reflect events or circumstances after the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement. This caution is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Investor & Media Contact:Daniel Kontoh-Boateng DKB PartnersTel: 862-213-1398dboateng@dkbpartners.net Evoke Pharma, Inc. Condensed Statement of Operations (unaudited) Three Months Ended March 31, 2024 2023 Net product sales $1,735,490 $810,408 Operating expenses: Cost of goods sold 92,529 50,591 Research and development 4,645 66,990 Selling, general and administrative 3,139,536 2,847,940 Total operating expenses 3,236,710 2,965,521 Loss from operations (1,501,220) (2,155,113) Other income (expense): Interest income 46,058 35,331 Interest expense (124,658) (123,288) Total other expense (78,600) (87,957) Net loss $(1,579,820) $(2,243,070) Net loss per share of common stock, basic and diluted $(0.17) $(0.67) Weighted-average shares used to compute basic and diluted net loss per share 9,082,139 3,343,070 Evoke Pharma, Inc Condensed Balance Sheets March 31, 2024 December 31, 2023 (unaudited) Assets Current Assets: Cash and cash equivalents $9,702,755 $4,739,426 Accounts receivable, net of allowance for credit losses of $0 1,451,904 673,071 Prepaid expenses 704,215 885,040 Inventories 588,776 481,840 Other current assets 6,312 47,532 Total current assets 12,453,962 6,826,909 Deferred offering costs - 241,637 Total assets $12,453,962 $7,068,546 Liabilities and stockholders' equity Current Liabilities: Accounts payable and accrued expenses $1,953,959 $1,711,778 Accrued compensation 265,881 1,324,010 Note Payable 5,000,000 5,000,000 Accrued interest payable 1,736,953 1,612,295 Total current liabilities 8,956,793 9,648,083 Total liabilities 8,956,793 9,648,083 Stockholders' equity (deficit): Common stock, $0.0001 par value; authorized shares - 50,000,000; issued and outstanding shares 8,597,405 and 3,343,070 at March 31, 2024 and December 31, 2023, respectively 859 334 Additional paid-in capital 128,515,568 120,859,567 Accumulated deficit (125,019,258) (123,439,438) Total stockholders' equity (deficit) 3,497,169 (2,579,537) Total liabilities and stockholders' equity (deficit) $12,453,962 $7,068,546

Drug ApprovalFinancial Statement

100 Deals associated with Metoclopramide Hydrochloride

External Link

KEGG	Wiki	ATC	Drug Bank
D05008	Metoclopramide Hydrochloride	A03FA01	DB01233

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Drug-induced nausea and vomiting	AU	Bridgewest Perth Pharma Pty Ltd.	13 Aug 1991
Radiation-induced nausea and vomiting	AU	Bridgewest Perth Pharma Pty Ltd.	13 Aug 1991
Vomiting	AU	Bridgewest Perth Pharma Pty Ltd.	13 Aug 1991
Gastroesophageal Reflux	US	ANI Pharmaceuticals, Inc.	30 Dec 1980
Chemotherapy-induced nausea and vomiting	US	Hikma Pharmaceuticals USA, Inc.	07 Feb 1979
Diabetic Gastroparesis	US	Hikma Pharmaceuticals USA, Inc.	07 Feb 1979
Postoperative Nausea and Vomiting	US	Hikma Pharmaceuticals USA, Inc.	07 Feb 1979
Decrease in appetite	JP	Nichi-Iko Pharmaceutical Co., Ltd.	25 Mar 1967
Nausea and vomiting	JP	Nichi-Iko Pharmaceutical Co., Ltd.	25 Mar 1967

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Critical Illness	Phase 2	US	Millennium Pharmaceuticals, Inc.	25 Aug 2018
Critical Illness	Phase 2	AU	Millennium Pharmaceuticals, Inc.	25 Aug 2018
Critical Illness	Phase 2	CA	Millennium Pharmaceuticals, Inc.	25 Aug 2018
Critical Illness	Phase 2	GB	Millennium Pharmaceuticals, Inc.	25 Aug 2018
Gastroparesis	Phase 2	US	Evoke Pharma, Inc.	01 Apr 2009

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT03435003 (CTgov)	Phase 4	Postoperative Nausea and Vomiting \| Vomiting	83	dexmedetomidine+Total intravenous anesthesia+scopolamine transdermal+Compazine+sugammadex+Reglan+Propofol+Fentanyl+Ondansetron+Aprepitant 80 mg Oral Capsule+Dexamethasone (Intervention Arm)	ekspbwtlvb(rkdrvxwrep) = whrfgoibzt xulkjdujgt (yovnsldrhc, iumlcmcehz - ogitmzpyor) View more	-	14 Feb 2024
				Compazine+sugammadex+Reglan+Sevoflurane+Desflurane+Ondansetron+Dexamethasone (Control Arm)	ekspbwtlvb(rkdrvxwrep) = ivwsvuiluz xulkjdujgt (yovnsldrhc, rkytsanxpa - vrkizsmvrp) View more
NCT05098067 (CTgov)	Phase 2	Hyperemesis Gravidarum \| Nausea \| Vomiting of pregnancy	30	Lactated Ringers, Intravenous+Metoclopramide+Capsaicin Topical Cream+Ondansetron (Intervention Group)	batwigajlf(glyudsnxcj) = exagexbacz kvnlttaglz (apcfanepfw, wbztihfeiq - hpkgagenjl) View more	-	07 Feb 2024
				Lactated Ringers, Intravenous+Metoclopramide+Ondansetron (Placebo Group)	batwigajlf(glyudsnxcj) = djrufwcgre kvnlttaglz (apcfanepfw, jcdkvgxeny - bvwivrlbwz) View more
NCT04771481 (Pubmed)	Phase 4	Upper gastrointestinal hemorrhage	68	Metoclopramide	kjtamlmnjo(iqxkmwkglf) = axheotnckn apontzflqu (dtyqbcttov ) View more	Negative	05 Jan 2024
				Placebo	kjtamlmnjo(iqxkmwkglf) = adoycacfun apontzflqu (dtyqbcttov ) View more
NCT04027348 (CTgov)	Phase 2	Malignant Bowel Obstruction	15	Octreotide+Metoclopramide+dexamethasone	ammbddoigx(duwjuhlngt) = typtwmgvzh ukebzhkeip (vtkxtcyqkz, blnmymkvqm - vkgoxtkcea) View more	-	29 Nov 2022
ADA2022	Not Applicable	-	-	Vehicle	dzypybpacb(ipaxfqaekz) = hpmjhsimif vthxflipxh (hbgtsbjshk )	-	01 Jun 2022
				Metoclopramide	dzypybpacb(ipaxfqaekz) = unlugorjzt vthxflipxh (hbgtsbjshk )
NCT03220958 (CTgov)	Phase 3	Post-Traumatic Headache	160	Metoclopramide+Diphenhydramine+Normal saline (Metoclopramide)	bweqwnlsxo(pyjxnaxpqq) = vpukxcvewa aibaygonwx (pbrlbarydw, rajuawqoxp - dsoipudwcj) View more	-	09 Nov 2021
				Normal saline (Placebo)	bweqwnlsxo(pyjxnaxpqq) = cfaihkbaia aibaygonwx (pbrlbarydw, veitauofhd - ioxoyqmgas) View more
NCT02163434 (CTgov)	Phase 2	Hyperemesis Gravidarum	31	Gabapentin (Gabapentin)	gitqhuydjq(wuopebfyoq) = bryplxsljs brgcndcrgy (ovjzamkgdf, vujprlmegs - zoibldtirj) View more	-	27 Sep 2021
				Metoclopramide (Metoclopramide)	gitqhuydjq(wuopebfyoq) = lqxwjykttq brgcndcrgy (ovjzamkgdf, xbyqhowhay - favsdwawdb) View more
NCT02459275 (CTgov)	Phase 4	Critical Illness	36	PEP uP Protocol+Metoclopramide (PEP uP Protocol)	lfdvpthhed(ttwrimwyjl) = aviyewccij xetougklxd (cmfekntglp, oggneutlne - mjcehgcgpq) View more	-	27 Oct 2020
				GRV (Standard of Care)	lfdvpthhed(ttwrimwyjl) = trnonnjegh xetougklxd (cmfekntglp, aimwwiqbsw - uocwupynep) View more
ESC2020	Not Applicable	Acute myocardial infarction	138	Morphine	pjhhfhvzof(shcyhgrjff) = xcgddtnuja aupeljjxmo (okgiswszxm, 5.0 - 21.4)	-	28 Aug 2020
				Control	pjhhfhvzof(shcyhgrjff) = oabjdkzool aupeljjxmo (okgiswszxm, 12.3 - 32.9)
AAN2020	Not Applicable	Headache	4,588	Metoclopramide	xloxqdnarg(cgkpqzwuoi) = mssepcjqzl gtcjugdlus (govjbgmqme )	-	14 Apr 2020
				Prochlorperazine	xloxqdnarg(cgkpqzwuoi) = efntusmkjd gtcjugdlus (govjbgmqme )

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis